Spyre Therapeutics Inc. $(SYRE)$, a clinical-stage biotechnology company, is set to participate in the Jefferies Global Healthcare Conference on June 4, 2025. The company, known for its advancements in antibody engineering and therapeutic combinations for the treatment of Inflammatory Bowel Disease and other immune-mediated diseases, will have its management present at a fireside session scheduled for 8:10 am ET.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.